These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6502166)

  • 1. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.
    Chalk JB; Ridgeway K; Brophy T; Yelland JD; Eadie MJ
    J Neurol Neurosurg Psychiatry; 1984 Oct; 47(10):1087-90. PubMed ID: 6502166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone: pharmacokinetics in neurological patients.
    Eadie MJ; Brophy TR; Ohlrich G; Tyrer JH
    Clin Exp Neurol; 1984; 20():107-18. PubMed ID: 6568935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortisol production during high dose dexamethasone therapy in neurological and neurosurgical patients.
    Brophy T; Chalk JB; Ridgeway K; Tyrer JH; Eadie MJ
    J Neurol Neurosurg Psychiatry; 1984 Oct; 47(10):1081-6. PubMed ID: 6502165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients.
    Brophy TR; McCafferty J; Tyrer JH; Eadie MJ
    Eur J Clin Pharmacol; 1983; 24(1):103-8. PubMed ID: 6832191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of dexamethasone with phenytoin.
    Lackner TE
    Pharmacotherapy; 1991; 11(4):344-7. PubMed ID: 1923918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review.
    Gattis WA; May DB
    Ann Pharmacother; 1996 May; 30(5):520-6. PubMed ID: 8740335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin-dexamethasone interaction: a previously unreported observation.
    Lawson LA; Blouin RA; Smith RB; Rapp RP; Young AB
    Surg Neurol; 1981 Jul; 16(1):23-4. PubMed ID: 7280966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetics of phenytoin during pregnancy.
    Lander CM; Smith MT; Chalk JB; de Wytt C; Symoniw P; Livingstone I; Eadie MJ
    Eur J Clin Pharmacol; 1984; 27(1):105-10. PubMed ID: 6489420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin/dexamethasone interaction.
    Vincent FM
    Lancet; 1978 Jun; 1(8078):1360. PubMed ID: 78122
    [No Abstract]   [Full Text] [Related]  

  • 11. Dexamethasone/phenytoin interactions: neurooncological concerns.
    Rüegg S
    Swiss Med Wkly; 2002 Jul; 132(29-30):425-6. PubMed ID: 12428189
    [No Abstract]   [Full Text] [Related]  

  • 12. Is misonidazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in RTOG 79-18 and RTOG 79-16?
    Nelson DF; Gillespie BW; Diener MD; Davis DR; Wasserman T; Phillips TL; Stetz J
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1731-4. PubMed ID: 6384162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of phenytoin: comparison between three preparations.
    Kitzes R; Ackerman Z; Levy M; Frumerman I; Shved A; Garty M
    Isr J Med Sci; 1985 Apr; 21(4):323-6. PubMed ID: 3997494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic optimisation of the treatment of neurocysticercosis.
    Sotelo J; Jung H
    Clin Pharmacokinet; 1998 Jun; 34(6):503-15. PubMed ID: 9646011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
    Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-induced weakness in patients with primary brain tumors.
    Dropcho EJ; Soong SJ
    Neurology; 1991 Aug; 41(8):1235-9. PubMed ID: 1866012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH; Patel TV; Fischer PA
    Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone.
    Na-Bangchang K; Vanijanonta S; Karbwang J
    Southeast Asian J Trop Med Public Health; 1995 Mar; 26(1):120-3. PubMed ID: 8525397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin bioavailability assessed by steady state serum concentrations.
    Halkin H; Gapany M; Dinai Y; Dany S
    Isr J Med Sci; 1985 Apr; 21(4):327-30. PubMed ID: 3997495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
    Jones DH; Bleehen NM; Workman P; Walton MI
    Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.